<DOC>
	<DOCNO>NCT02918318</DOCNO>
	<brief_summary>The purpose study evaluate efficacy fix dose intranasal esketamine compare intranasal placebo , add-on oral antidepressant Japanese participant treatment-resistant depression ( TRD ) , improve depressive symptom .</brief_summary>
	<brief_title>A Study Evaluate Efficacy , Safety Tolerability Fixed Doses Intranasal Esketamine Japanese Participants With Treatment Resistant Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Treatment-Resistant</mesh_term>
	<criteria>At start screen phase , participant must meet Diagnostic Statistical Manual Mental Disorders ( DSM5 ) diagnostic criterion recurrent major depressive disorder ( MDD ) , without psychotic feature , base upon clinical assessment confirm Mini International Neuropsychiatric Interview ( MINI ) The participant 's current major depressive episode , depression symptom severity ( MADRS total score great equal [ &gt; = ] 28 require ) , antidepressant treatment response current depressive episode , must confirm use SAFER interview Participant must medically stable basis clinical laboratory test , physical examination , medical history , vital sign ( include blood pressure ) , pulse oximetry , 12lead electrocardiogram ( ECG ) perform screen phase A woman childbearing potential must negative highly sensitive serum Beta ( β ) human chorionic gonadotropin [ βhCG ] test start screen phase negative urine pregnancy test must obtain first dose study drug Day 1 doubleblind induction phase prior randomization Contraceptive use men woman consistent local regulation regard use contraceptive method participant participate clinical study Participant receive vagal nerve stimulation receive deep brain stimulation current episode depression Participant previously receive esketamine ketamine treatment MDD Participant homicidal ideation/intent , per investigator 's clinical judgment , suicidal ideation intent act within 6 month prior start screen phase Participant history moderate severe substance alcohol use disorder accord DSM5 criterion , except nicotine caffeine , within 6 month start screen phase Participant current past history seizure disorder ( uncomplicated childhood febrile seizures sequelae exclusionary )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>